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Abstract The high rate of interval malignancies urges for
new screening methods for women at high risk for breast
cancer. Nippleaspiration providesdirect access tothe breast
tissue and its DNA, and therefore is a likely candidate, but
clinical applications have been limited by the failure to
obtain nipple aspiration ﬂuid from most women. We per-
formed oxytocin-assisted nipple aspiration in 90 women at
increased risk for breast cancer based on family history or
genetic test results (n = 63) and/or previous breast cancer
(n = 34). Nipple ﬂuid was obtained from 81/90 women
(90%) and bilaterally in 77%. Mean discomfort rating was
0.6 (on a 0–10 scale), which was signiﬁcantly lower than for
mammography or MRI. These ﬁndings suggest that a new
toolforbiomarkerdetectioninoxytocin-assistednippleﬂuid
of women at high risk for breast cancer is at hand.
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Abbreviations
DCIS Ductal carcinoma in situ
NAF Nipple aspirate ﬂuid
QM-MSP QuantitativemultiplexmethylationspeciﬁcPCR
RPFNA Random periareolar ﬁne needle aspiration
Introduction
Breast cancer is the most prevalent cancer for women in the
Western world, accounting for 519,000 deaths worldwide
each year [1]. Approximately one in eight women will
eventually develop breast cancer, but for some women this
risk is even higher. A hereditary predisposition is the most
important risk factor, with a lifetime risk of developing
breast cancer up to 80% in women known to carry a
BRCA1 or BRCA2 germline mutation [2].
Several screening and prevention options are available
to these women, in order to either prevent the development
of breast cancer or detect it at an early stage. However,
until now, screening programs are only partly effective and
in one out of four in high-risk women interval malignancies
are detected [3]. Prophylactic mastectomy and salpingo-
oophorectomy have been proven to effectively decrease the
risk in women at high risk, but the morbidity associated
with this procedure discourages many women to choose
this option.
A screening method that gives access to the tissue in
which breast cancer arises could add value to the existing
methods and increase the rate of breast cancer detection at
an early stage [4]. Nipple Aspirate Fluid (NAF), containing
breast epithelial cells, free DNA, secreted proteins and
hormones is produced in the breast ducts of non-lactating
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developed to obtain this ﬂuid, such as non-invasive nipple
aspiration, ductal lavage and Random Periareolar Fine
Needle Aspiration (RPFNA). Nipple aspiration was previ-
ously reported to be only feasible in a small part of the
population [5, 6]. The other two techniques showed higher
success percentages, but their invasive nature is a serious
drawback.
From a previous pilot study we reported that, using
oxytocin nasal spray, we were able to obtain nipple ﬂuid in
94% out of 67 healthy volunteers, of which 75% yielded
ﬂuid bilaterally [7]. The procedure was very well tolerated.
Here we report the initial results of a prospective study on
oxytocin-assisted nipple aspiration in women with a mod-
erate to high breast cancer risk.
Materials and methods
Study population
This study is part of a project that aims to explore the
possibilities of monitoring development of epigenetic
changes in nipple aspirates, with the ultimate goal to
optimally schedule preventive (or refrain from) breast
surgery in high-risk women. To this end we are assessing
promoter hypermethylation in nipple aspirates of high-risk
women, of which some will undergo preventive or thera-
peutic surgery. This will enable assessing the correlation
between methylation patterns and the development of
(pre)malignant lesions in this group. Oxytocin-assisted
nipple aspiration is performed annually. Besides, partici-
pants will undergo regular radiological and/or clinical
examination as they were used to. Timing of breast surgery
will be agreed between patient and oncologist based on
usual clinical and radiological ﬁndings, blinded to the
results of the nipple aspirate analyses. The study protocol
of this study was approved by the Hospital’s Ethics
Committee and written informed consent was obtained
from all participants. This report is a summary of the
baseline nipple aspiration experience of the ﬁrst 90 subjects
enrolled between August 2008 and July 2009.
Eligibility criteria
Women were considered at increased risk and included in
this study if they were carriers of a BRCA1 or BRCA2
germline mutation, had a pedigree-based risk C20%, or had
a history of Ductal Carcinoma in Situ (DCIS) or invasive
breast cancer. Pregnancy and bilateral mastectomy were
exclusion criteria. We did not exclude women that previ-
ously underwent other forms of breast surgery, radiother-
apy, chemotherapy or hormonal treatment.
Nipple aspiration procedure
Anesthetic cream (Emla) was applied onto the nipple while
the breasts were warmed for 10 min. The subjects were
administered 4 IE of oxytocin into both nostrils. The nipple
was gently wiped with a dekeratinizing agent in order to
remove keratin plugs and subsequently cleansed with eth-
anol. A suction cup (aspirator) was placed over the nipple.
Repeated gentle suction by a syringe (10–50 cc) drew ﬂuid
to the nipple surface, where droplets were collected by
capillary tubes. The entire procedure was repeated at the
other breast. Quantitative Multiplex Methylation Speciﬁc
PCR (QM-MSP) for RASSF1A, SCGB3A1 and APC was
performed on 50 randomly selected nipple ﬂuid samples
obtained in this study as described before [8].
Questionnaires
A questionnaire, addressing breast cancer risk factors and
factors that might inﬂuence the success of the procedure
was ﬁlled out before nipple ﬂuid aspiration. After aspira-
tion participants rated the experienced discomfort during
different stages of the procedure and other screening pro-
cedures from 0 (‘‘no discomfort at all’’) to 10 (‘‘the worst I
can imagine’’).
Statistical analysis
A paired T-test was used to compare the discomfort scores
of different procedures. Fisher’s exact and Chi-square tests
were used to examine the association between NAF
yielding and potential predictive values. For this analysis,
subgroups from Table 1 were pooled because of low
numbers. A selection of independent variables (see
Table 3) was used in a logistic regression analysis using
backward selection procedure, retaining covariates with
P B 0.10, for the right and the left breast separately. SPSS
15.0 for Windows was used for statistical analysis,
regarding two-sided P B 0.05 as signiﬁcant.
Results
A total of 90 women at increased risk were included in this
study. Sixty-three women had a family history of breast
cancer, six of them were known carriers of a germline
BRCA1 mutation and six had a BRCA2 mutation. Twelve
women had a history of DCIS and 22 women previously
had invasive breast cancer. Participants were 21–72 years
old (mean 48 years). All baseline characteristics are shown
in Table 1.
The procedure was very well endured. Mean discomfort
rating for the total procedure was 0.6, which was
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123Table 1 Patient characteristics of 90 patients at increased risk for
invasive breast cancer undergoing oxytocin-assisted nipple ﬂuid
aspiration
n (%)
Age (years)
\40 22 (24%)
40–49 25 (28%)
C 50 43 (48%)
BRCA germline mutation
None detected 28 (31%)
BRCA1 6 (7%)
BRCA2 6 (7%)
BRCA1 in family
a 2 (2%)
BRCA2 in family
a 1 (1%)
Pedigree-based risk
None 27 (30%)
Moderate (20-30%) 12 (13%)
High (30-40%) 17 (19%)
Known mutation ([40%) 18 (20%)
Personal history of breast cancer
No 56 (62%)
DCIS 12 (13%)
Invasive carcinoma 22 (24%)
Spontaneous nipple discharge
Yes 11 (12%)
No 79 (88%)
Number of live births
0 30 (33%)
1–2 43 (48%)
C 3 17 (19%)
Age at ﬁrst birth (years)
\25 18 (20%)
25–29 27 (30%)
C 30 15 (17%)
Age at menarche (years)
\12 27 (30%)
12–14 29 (32%)
[14 32 (36%)
Menopausal status
Premenopausal 42 (47%)
Postmenopausal 48 (53%)
Menstrual cycle day
b
1–7 12 (13%)
7–14 4 (4%)
14–21 9 (10%)
[21 11 (12%)
Age at menopause (years)
\45 16 (18%)
45–50 16 (18%)
[50 16 (18%)
Table 2 Discomfort of nipple aspiration compared to other screening
procedures for 90 patients at high risk for invasive breast cancer
undergoing oxytocin-assisted nipple ﬂuid aspiration
Number
of women
Mean score (SE) P-value
a
Nipple aspiration 90 0.6 (0.1) –
Breast feeding 51 1.8 (0.3) \0.001
Physical examination 83 1.1 (0.2) 0.004
Mammography 83 4.9 (0.3) \0.001
MRI 31 2.6 (0.4) \0.001
a Paired samples T-test
Table 1 continued
n (%)
Previous breast feeding
Yes 51 (57%)
No 39 (43%)
Current oral contraceptive use
Yes 14 (16%)
No 76 (84%)
Current hormonal replacement therapy
Yes 2 (2%)
No 88 (98%)
Size breast
Small (A–B) 24 (27%)
Normal (C–D) 58 (64%)
Large[D 8 (9%)
Prophylactic oophorectomy
Yes 18 (20%)
No 72 (80%)
Previous chemotherapy
Yes 12 (13%)
No 78 (87%)
Previous radiotherapy
Yes 23 (26%)
No 67 (74%)
Breast surgery
None 50 (56%)
Excision biopsy 6 (7%)
Breast conserving 16 (18%)
Ablation 17 (19%)
Other 1 (1%)
a These women have a 50% risk of being a carrier, but have chosen
not to undergo testing (yet)
b Six premenopausal women did not have a menstrual cycle, due to
contraceptives (hormonal Intrauterine Device etc.)
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123signiﬁcantly lower than breast feeding (1.8), physical
examination by a medical oncologist or surgeon (1.1), MRI
(2.6) and mammography (4.9; Table 2). No side effects
were reported.
Nipple ﬂuid was obtained from 81 out of 90 women
(90%) and bilaterally in 77%. QM-MSP for RASSF1,
SCGB3A1 and APC was possible in all 50 samples that we
have analyzed. From the 15 women that were known to
carry a BRCA1 or BRCA2 mutation or that have family
members that are known to be carriers, 14 women yielded
bilaterally upon aspiration; in one woman nipple aspiration
was only successful in one breast. Characteristics that made
women signiﬁcantly less likely to yield nipple ﬂuid upon
aspiration, were not having a family history of breast
cancer (P = 0.002), postmenopausal status (P = 0.03) and
previous surgery (excision biopsy, breast conserving sur-
gery or other surgery of the breast) on the right side of the
breast (P = 0.002; Table 3). Age did not signiﬁcantly
inﬂuence the success of the procedure (P = 0.08).
Using logistic regression, no factor could be identiﬁed
that signiﬁcantly contributed to the success of nipple
aspiration in the left breast in multivariate analysis. For the
right breast, only an increased pedigree-related risk (B 2.6;
P = 0.02) correlated to the success rate of the aspiration in
a multivariate model.
Discussion
Here we describe our ﬁndings of performing oxytocin-
assisted nipple aspiration in a cohort of 90 high-risk
women. We were able to obtain nipple ﬂuid in 90% of
high-risk women not selected for age, hormonal factors or
previous therapy. A negative effect of surgery of the right
breast on NAF yielding was shown, but this effect was not
signiﬁcant in the left breast. Furthermore, in 56% of
women that previously underwent surgery of the right
breast aspiration was still successful. Therefore, previous
surgery is not a reason to exclude women from our study.
Similarly, although postmenopausal status and not having a
family history for breast cancer decreased the likelihood to
yield NAF, 83% of postmenopausal women and 78% of
women without a family history of breast cancer still
yielded NAF.
A recent article by Loud et al. [9] reported failure to
obtain nipple ﬂuid (not supported by oxytocin) in the large
majority of women from BRCA families. In this study,
only 45 out of 171 women from BRCA families (26%)
yielded NAF, 63% (107/171) could have a duct cannulated
for ductal lavage, while cytologically evaluable samples
were obtained in only 41% of these women. Women
without a prior breast cancer history had an increased
likelihood of yielding NAF and the presence of NAF was
an independent correlate of ductal lavage cell count ade-
quacy. From these data, the authors concluded that ductal
lavage is unlikely to be useful in breast cancer screening
among BRCA1/2 mutation carriers.
Table 3 Predictive factors for successful oxytocin-assisted nipple
aspiration in 90 patients at increased risk for invasive breast cancer
undergoing nipple ﬂuid aspiration
Aspiration procedure outcome P-value
Unsuccessful (n) Successful (n)
Pedigree-based risk
Not increased 6 21
Increased 0 47 0.002
a
Spontaneous nipple discharge
Yes 0 11
No 9 70 0.59
a
Parity
Nulliparous 2 28
Parous 7 53 0.71
a
Menopausal status
Premenopausal 1 41
Postmenopausal 8 40 0.03
a
Previous breast feeding
Yes 7 44
No 2 37 0.29
a
Current oral contraceptive
Yes 0 14
No 9 67 0.35
a
Previous chemotherapy
Yes 2 10
No 7 71 0.34
a
Previous radiotherapy
Yes 3 20
No 6 61 0.69
a
Breast surgery left
b
Yes 6 16
No 8 51 0.15
c
Breast surgery right
b
Yes 7 9
No 7 59 0.002
c
a Fisher’s exact test
b Ablation cases were excluded for this analysis (analysis for left and
right breast separately)
c Chi-square test
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123The present study provides quite different results. We
believe that vacuum-assisted nipple aspiration, if feasible,
is to be preferred over ductal lavage because of its non-
invasive nature. Unlike most previous studies, we do not
assess cytology, but are focusing on methylation aberra-
tions in our nipple ﬂuid samples. As reported by Loud et al.
[9], multiple studies have questioned the reproducibility
and clinical value of cytology in nipple ﬂuid. Moreover,
Fackler et al. [10] showed that, compared to cytology,
analyzing promoter methylation in ductal lavage cells
doubled the detection rate of breast cancer. In a previous
study, Dooley et al. [11] were able to obtain nipple ﬂuid in
a comparable cohort in 84% of women, but in this study
only 27% yielded adequate samples for diagnosis.
In conclusion, from our experience oxytocin-assisted
nipple aspiration is a very well tolerated non-invasive
procedure to obtain nipple ﬂuid in virtually all women,
including BRCA1 and BRCA2 mutation carriers. The high
success rate of the procedure is not restricted by age,
reproductive factors or previous therapy and suggests that a
new tool for biomarker detection in nipple ﬂuid of women
at increased risk for breast cancer is at hand.
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